What is Veklury (remdesivir), and how does it work?
Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
What are the side effects of Veklury?
Hypersensitivity Including Infusion-related and Anaphylactic Reactions
Hypersensitivity reactions, including infusion-related and anaphylactic reactions, have been observed during and following administration of Veklury. Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent these signs and symptoms. Monitor patients under close medical supervision for hypersensitivity reactions during and following administration of Veklury. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of Veklury and initiate appropriate treatment. The use of Veklury is contraindicated in patients with known hypersensitivity to Veklury or any components of the product.
Increased Risk of Transaminase Elevations
Transaminase elevations have been observed in healthy volunteers who received 200 mg of Veklury followed by 100 mg doses for up to 10 days; the transaminase elevations were mild (Grade 1) to moderate (Grade 2) in severity and resolved upon discontinuation of Veklury. Transaminase elevations have also been reported in patients with COVID-19 who received Veklury. Because transaminase elevations have been reported as a clinical feature of COVID-19, and the incidence was similar in patients receiving placebo versus Veklury in clinical trials of Veklury, discerning the contribution of Veklury to transaminase elevations in patients with COVID-19 can be challenging.
Perform hepatic laboratory testing in all patients before starting Veklury and while receiving Veklury as clinically appropriate
The following adverse reactions have been identified during use of Veklury under Emergency Use Authorization:
What is the dosage for Veklury?
Recommended Dosage in Adults and Pediatric Patients 12 Years of Age and Older and Weighing at Least 40 kg
The recommended dosage for adults and pediatric patients 12 years of age and older and weighing at least 40 kg is a single loading dose of Veklury 200 mg on Day 1 via intravenous infusion followed by once-daily maintenance doses of Veklury 100 mg from Day 2 via intravenous infusion.
The recommended treatment duration for patients not requiring invasive mechanical ventilation
and/or extracorporeal membrane oxygenation (ECMO) is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days.
- The recommended total treatment duration for patients requiring invasive mechanical ventilation and/or ECMO is 10 days.
- Veklury must be diluted prior to intravenous infusion.
What drugs interact with Veklury?
Drug-drug interaction trials of Veklury and other concomitant medications have not been conducted in humans. Remdesivir and its metabolites are in vitro substrates and/or inhibitors of certain drug metabolizing enzymes and transporters. The clinical relevance of these in vitro assessments has not been established.
Is Veklury safe to take while pregnant or breastfeeding?
Available data from published case reports and compassionate use of remdesivir in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals.
Pregnant women hospitalized with COVID-19 are at risk for serious morbidity and mortality.
There are no available data on the presence of remdesivir in human milk, the effects on the breastfed infant, or the effects on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Veklury and any potential adverse effects on the breastfed child from Veklury or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.
Veklury (remdesivir) is a synthetic molecule in the antiviral class of medications. It is the first approved medication for treatment of the COVID-19 coronavirus pandemic disease.
Multimedia: Slideshows, Images & Quizzes
Novel Coronavirus (COVID-19) Prevention: Frequently Asked Questions
Why is coronavirus considered dangerous? What are symptoms you should look for? Take this quiz to learn how to protect yourself.
Coronavirus COVID-19 (SARS-CoV-2) Pandemic Outbreak: What You Need to Know
A new strain of coronavirus (COVID-19, SARS-CoV-2) was reported from Wuhan, China in December, 2019. This outbreak of respiratory...
Coronavirus COVID-19 (SARS-CoV-2): The Latest News, Updates and Information
See the latest news updates and information on the Coronavirus COVID-19 outbreak. Learn about symptoms, prevention, possible...
Related Disease Conditions
COVID-19 (Coronavirus, 2019-nCoV)
Infection with COVID-19 (2019 novel coronavirus, 2019-nCoV) causes respiratory problems in humans. Transmission of COVID-19 occurs mainly through contact with respiratory sections from an infected person, however, fecal contamination may also spread the virus. Symptoms start off flu-like and progress to coughing, fever, shortness of breath, shaking chills, headache, loss of sense of taste and/or smell, muscle pain, and sore throat. Treatment focuses on supportive care and symptom relief.
COVID-19 (Coronavirus) Prevention Tips
COVID-19 is a novel coronavirus that spreads from person to person via infected respiratory droplets. The main symptoms of COVID-19 infection include cough, fever, and shortness of breath. Occasionally, people infected with COVID-19 may experience diarrhea, a sore throat, a runny or stuffy nose, or aches and pains. Avoiding contact with infected people, social distancing, not touching your face, frequent hand washing, cleaning, and disinfecting of frequently touched surfaces can help to reduce your risk of contracting the 2019 novel coronavirus.
COVID-19 vs. Flu vs. Cold
When you're feeling sick, it can be difficult to distinguish the symptoms of a COVID-19 infection from the symptoms of the common cold or the flu (influenza). While fever is common with the flu and COVID-19, sneezing is typically only associated with colds. Though sore throats are typical with colds, they are uncommon with COVID-19 infections and the flu.
COVID-19 vs. Allergies
Though there is some overlap in allergy and COVID-19 signs and symptoms there are also significant differences. Symptoms that they have in common include headache, fatigue, tiredness, shortness of breath, wheezing, and sore throat. Fever does not occur with allergies but is one of the defining symptoms of COVID-19 infections.
Treatment & Diagnosis
Prevention & Wellness
- Remdesivir Doesn't Reduce COVID-19 Patients' Risk of Death: Study
- Remdesivir Speeds Recovery for COVID Patients
- Anti-Inflammatory Drug May Shorten Recovery Time for COVID-19 Patients Taking Remdesivir
- Does Remdesivir Work Against COVID-19?
- Gilead Seeks FDA Approval for Remdesivir
- U.S. Grab of Only COVID-19 Treatment Outrages Health Experts
- Inhaled Remdesivir May Allow COVID-19 Patients to Be Treated at Home
- Hydroxychloroquine-Remdesivir Combo Dangerous for COVID-19 Patients: FDA
- COVID-19 Drug Studies Questioned
- Company Says Remdesivir Helps Moderately Sick COVID-19 Patients
- Remdesivir Will Not Be Enough to Curb COVID-19, Study Finds
- Combining Remdesivir With Other Meds Could Boost COVID-Fighting Power
- FDA Approves Emergency Use of Remdesivir for COVID-19
- Will Remdesivir Help COVID-19 Patients? Two Reports Provide Different Answers
- After Trump Hypes Use of a Lupus Med Against COVID-19, Lupus Patients Face Shortages
- Premature Posting of Remdesivir Findings Were 'Inconclusive,' Drug Maker Says
- Lots of Drugs Are Being Tested Against COVID-19 -- But Will Any Work?
- More Good News on Remdesivir's Power to Treat COVID-19
- The Lowdown on COVID-19 Treatments
- Why Remdesivir Might Be a Good Bet Against COVID-19
- COVID-19 Daily: Remdesivir Data Published, World Leader Recovers
- U.S. Passes Italy With Most Coronavirus Deaths, Small Study Shows Promise of Remdesivir
- Clinical Trial to Investigate Nitric Oxide Treatment of COVID-19
- Does COVID-19 Drug Touted by Trump Really Work? New Trial Aims to Find Out
- Tocilizumab (Actemra) for COVID-19 Coronavirus Treatment
- Trials Begin for Potential COVID-19 Drug Remdesivir
- Another COVID-19 Vaccine Being Tested in Mice
- Test for Coronavirus Antibodies Approved by FDA
- What COVID-19 Prevention and Treatment Guidelines From China Can Teach Us
Latest MedicineNet News
Daily Health News
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.